Document is current

Article History

Received: 13 March 2019

Accepted: 31 October 2019

First Online: 21 November 2019

Ethics approval and consent to participate

: Ethical approval was given by the institutional ethics committee of the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and the institutional review board of Okayama University Hospital (approval number KEN1608–010), and by the Okayama Psychiatric Medical Center (approval number 27–38). All participants provided written informed consent.

: Not applicable.

: YH has nothing to disclose related to this paper. MF1 reports grants from: Okayama Health Foundation, Novartis Pharma, Research for Promotion of Cancer Control Programs, and Eisai Co., Ltd. during this study; and personal fees from: Mochida Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Sentan Igaku-sha Ltd., Igaku-Shoin Ltd., Iyaku (Medicine and Drug) Journal Co., Ltd. outside the submitted work. RS reports personal fees from Kagakuhyronsha Co., Ltd., Medical Review Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Igaku Shoin Co., Ltd. outside the submitted work. KK reports personal fees from Mochida Pharmaceutical Co., Ltd. outside the submitted work. NY reports grants from Okayama Health Foundation, Novartis Pharma, Research for Promotion of Cancer Control Programs, and Eisai Co., Ltd. during this study; grants from the Japanese Ministry of Education, Science, and Technology; grants and personal fees from Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; grants from Astellas Pharma Inc., and grants and personal fees from MSD KK and Pfizer Inc.; personal fees from Meiji Seika Pharma Co., Ltd., Janssen Pharmaceutical KK, Hisamitsu Pharmaceutical Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Tsumura & Co.; and grants and personal fees from Takeda Pharmaceutical Co., Ltd. outside the submitted work. MI reports grants from Okayama Health Foundation, Novartis Pharma, Research for Promotion of Cancer Control Programs during this study; grants and personal fees from Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Eisai Co., Ltd., and MSD KK; grants from Astellas Pharma Inc. and Daiichi Sankyo Co., Ltd.; personal fees from Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Novartis Pharma, Otsuka Pharmaceutical Co., Ltd., Yoshitomiyakuhin Corporation, and Technomics, Inc., outside the submitted work. The other authors have nothing to disclose related to this paper.